Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Allakos's share price for the quarter that ended in Dec. 2024 was $1.21. Allakos's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 89.65 Mil. Therefore, Allakos's market cap for the quarter that ended in Dec. 2024 was $108.48 Mil.
Allakos's quarterly market cap
declined
from Jun. 2024 ($88.85 Mil) to Sep. 2024 ($58.36 Mil) but then
increased
from Sep. 2024 ($58.36 Mil) to Dec. 2024 ($108.48 Mil).
Allakos's annual market cap
declined
from Dec. 2022 ($718.96 Mil) to Dec. 2023 ($239.56 Mil) and
declined
from Dec. 2023 ($239.56 Mil) to Dec. 2024 ($108.48 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Allakos's Enterprise Value for Today is $-54.16 Mil.
Allakos Market Cap Historical Data
The historical data trend for Allakos's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allakos's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allakos's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allakos's Market Cap distribution charts can be found below:
* The bar in red indicates where Allakos's Market Cap falls into.
Allakos Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Allakos's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allakos (NAS:ALLK) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Allakos Market Cap Related Terms
Thank you for viewing the detailed overview of Allakos's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALLK has been successfully added to your 